| Walter Barrett Jones, PHARMD | |
|
1300 N Main St, Newton, KS 67114-1916 | |
| (316) 281-9356 | |
| Not Available |
| Full Name | Walter Barrett Jones |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1300 N Main St, Newton, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073392643 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-100797 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Walter Barrett Jones, PHARMD 1300 N Main St, Newton, KS 67114-1916 Ph: () - | Walter Barrett Jones, PHARMD 1300 N Main St, Newton, KS 67114-1916 Ph: (316) 281-9356 |
News Archive
Today, the Chan Zuckerberg Initiative announced $4.5 million in funding to support 30 pairs of researchers to collaborate and apply novel approaches for gaining greater insight into neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS.
Joan Broderick, Ph.D., Research Associate Professor, Department of Psychiatry and Behavioral Sciences at Stony Brook University, has received a $606,000 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.
The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients.
OXIS INTERNATIONAL, INC. announced today that the Company has retained Quinn Emanuel Urquhart Oliver & Hedges ("Quinn Emanuel") to enforce all patents related to the unique benefits of its potent antioxidant compound L-Ergothioneine ("ERGO").
NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion demonstrates bioequivalence and improved tolerability when compared with Sandimmune Injection.
› Verified 8 days ago
Daniel Lindenmeyer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1410 S Kansas Ave, Newton, KS 67114 Phone: 316-284-3725 Fax: 316-284-3728 | |
Brian Steventon, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1216 N Main St, Newton, KS 67114 Phone: 316-283-6770 | |
Heath Allen Kerr, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1216 N Main St, Newton, KS 67114 Phone: 316-283-6770 Fax: 316-284-3719 | |
Miss Diana Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1300 N Main St, Newton, KS 67114 Phone: 316-281-9356 | |
Mrs. Christen Martens, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1216 N Main St, Newton, KS 67114 Phone: 316-283-6771 Fax: 316-284-3719 | |
Tina Reese, PHARMICIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 720 Medical Center Dr, Newton, KS 67114 Phone: 316-283-6103 Fax: 316-283-1333 |